Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)

We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Lymphoma Myeloma Leuk
Autors principals: Ramos, Juan C., Sparano, Joseph A., Rudek, Michelle A., Moore, Page C., Cesarman, Ethel, Reid, Erin G., Henry, David, Ratner, Lee, Aboulafia, David, Lee, Jeanette Y., Ambinder, Richard F., Mitsuyasu, Ronald, Noy, Ariela
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697160/
https://ncbi.nlm.nih.gov/pubmed/29426719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.01.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars